Movatterモバイル変換

[0]ホーム

Jump to content

Bleselumab

Edit links

From Wikipedia, the free encyclopedia

Monoclonal antibody

Pharmaceutical compound

Bleselumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CD40
Clinical data
Other names	ASKP1240
ATC code	none
Identifiers
CAS Number	1453067-91-8
ChemSpider	none
UNII	AS3AZ5R46K
KEGG	D11357
Chemical and physical data
Formula	C₆₄₁₂H₉₉₀₆N₁₆₉₀O₂₀₁₈S₃₈
Molar mass	144175.87 g·mol⁻¹

Bleselumab (INN;^[1] development codeASKP1240) is a human monoclonal antibody designed for the prevention oforgan transplant rejection.^[2]^[3]

This drug was developed by Kyowa Kirin Pharmaceutical Development Inc.^[4]

References

[edit]

^World Health Organization (2015)."International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113"(PDF).WHO Drug Information.29 (2).
^Wojciechowski D, Vincenti F (November 2016). "Current status of costimulatory blockade in renal transplantation".Current Opinion in Nephrology and Hypertension.25 (6):583–590.doi:10.1097/MNH.0000000000000268.PMID 27517137.S2CID 4379881.
^Malvezzi P, Jouve T, Rostaing L (November 2016)."Costimulation Blockade in Kidney Transplantation: An Update".Transplantation.100 (11):2315–2323.doi:10.1097/TP.0000000000001344.PMC 5084636.PMID 27472094.
^Statement On A Nonproprietary Name Adopted By The USAN Council - Bleselumab,American Medical Association.

Monoclonal antibodies for theimmune system

Immune system

Human	Immunosuppression:Abrilumab Adalimumab^# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Garadacimab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Nipocalimab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation:Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other:Bertilimumab Ontamalimab Zanolimumab Combination:Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive:Apolizumab^§ Aselizumab Atezolizumab Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab^‡ Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Frexalimab^† Inebilizumab Itolizumab Lampalizumab^† Letolizumab Ligelizumab^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab (+berahyaluronidase alfa) Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab^† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Immune activation:Dostarlimab Other:Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatorylesions

Mouse	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thismonoclonal antibody–related article is astub. You can help Wikipedia byadding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Bleselumab&oldid=1124068672"

Categories:

Hidden categories:

[8]ページ先頭